We randomly assigned patients with sudden deafness refractory to systemic corticosteroids to receive either gelatin hydrogels impregnated with IGF-1 in the middle ear ( 62 patients ) or four intratympanic injections with dexamethasone ( Dex ; 58 patients ) .